CLINICAL TRIALS PROFILE FOR BENZOYL PEROXIDE; ERYTHROMYCIN
✉ Email this page to a colleague
All Clinical Trials for benzoyl peroxide; erythromycin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00823901 ↗ | Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea | Completed | Medicis Pharmaceutical Corporation | Phase 2/Phase 3 | 2009-02-01 | The purpose of this study is to determine whether Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel are effective and safe in the treatment of papulopustular rosacea. |
| NCT00823901 ↗ | Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea | Completed | Massachusetts General Hospital | Phase 2/Phase 3 | 2009-02-01 | The purpose of this study is to determine whether Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel are effective and safe in the treatment of papulopustular rosacea. |
| NCT01706263 ↗ | U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne | Completed | GlaxoSmithKline | Phase 4 | 2009-08-01 | One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or not improving symptoms fast enough), tolerability issues or adverse effects (eg, erythema, dryness, or peeling of the skin), a lack of understanding of the instructions for use, or product cost/availability. Whatever the reason, poor compliance translates to decreased efficacy and increased frustration on the part of the user. The current study will evaluate the efficacy and tolerability of MAXCLARITY II, an over the counter, topical benzoyl peroxide (BPO) product line, in subjects with acne. |
| NCT01706263 ↗ | U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne | Completed | Stiefel, a GSK Company | Phase 4 | 2009-08-01 | One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or not improving symptoms fast enough), tolerability issues or adverse effects (eg, erythema, dryness, or peeling of the skin), a lack of understanding of the instructions for use, or product cost/availability. Whatever the reason, poor compliance translates to decreased efficacy and increased frustration on the part of the user. The current study will evaluate the efficacy and tolerability of MAXCLARITY II, an over the counter, topical benzoyl peroxide (BPO) product line, in subjects with acne. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for benzoyl peroxide; erythromycin
Condition Name
Clinical Trial Locations for benzoyl peroxide; erythromycin
Trials by Country
Clinical Trial Progress for benzoyl peroxide; erythromycin
Clinical Trial Phase
Clinical Trial Sponsors for benzoyl peroxide; erythromycin
Sponsor Name
